The news: Veeva is acquiring agentic AI company Ostro for $100 million to boost its AI capabilities for healthcare providers and patients. Ostro will operate as an independent division and develop integrated workflows over time.

Why it matters: Veeva is the leading customer relationship management (CRM) platform for pharma marketers to manage sales reps, content, and relationships with healthcare providers on the back end. Ostro’s specialized AI adds a front door and direct connection to healthcare providers’ digital engagement, enabling two-way conversations between pharma brands and physicians about drug mechanisms of action, clinical evidence, or health plan coverage. Ostro AI draws ​​from existing MLR-approved content on prescription brand websites.

Demand is growing across pharma and healthcare for AI-enabled communications and marketing, with a focus on compliant, engaging tools for providers and patients.

• More than half of pharma companies (51%) have rolled out or piloted AI in commercial use cases, and 37% report having clear genAI strategies, according to a Bain & Co. report published in August.
• 59% of pharma companies plan to adopt AI specifically for healthcare provider engagement.

Implications for healthcare and pharma marketers: While generic AI chatbots like ChatGPT often handle initial consumer health inquiries, commercial AI use in healthcare and pharma requires greater precision and regulatory guardrails. Specialized solutions like Ostro’s are built for that environment, combining compliant conversational frameworks with scientific and clinical content.

If integrated into Veeva’s workflows, those capabilities could help life sciences companies scale regulated, AI-driven engagement more comprehensively within the systems they already rely on.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.